effect of highly active antiretroviral therapy on neutrophil/lymphocyte ratio using white rabbit

Clicks: 170
ID: 239858
2017
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Background: There is an increasing reliance on neutrophil/lymphocyte ratio (NLR) as a prognostic marker in certain diseases. Observations have suggested the effects of administering highly active antiretroviral therapy (HAART) to human immunodeficiency virus (HIV) patients to be beneficial as well as having its side effects. Hence, this study is designed to examine the relationship of NLR of HAART in the management and disease progression of HIV infection. Materials and Methods: Twenty male white rabbits weighting between 0.8 and 1.8 kg were randomly assigned to five Groups A, B, C, D, and E with four animals per group. Two milliliters of venous blood was aseptically collected before HAART administration and on days 5, 10, 15, and 20 of treatment. Groups B, C, D, and E received graded doses of 15, 20, 25, and 34 mg/kg body weight of the drug combinations (efavirenz, lamivudine, and tenofovir disoproxil fumarate tablets once daily for 20 days). Neutrophil/lymphocyte counts were determined using hematology autoanalyzer. Results: Showed a significant reduction (P< 0.05) in NLR before HAART administration (controls) when compared to administration of HAART at 15, 20, 25, and 35 mg/kg 5 days after drug administration. The same trend was observed in the various groups at 10, 15, and 20 days after drug administration. Conclusion: Administration of HAART has a significant association on NLR.
Reference Key
osime2017saheleffect Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Evarista Odaburhine Osime;Silvanus Olu Innih
Journal nurse researcher
Year 2017
DOI
10.4103/1118-8561.215034
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.